Saluda Medical: First “Pacemaker for the Spine” Gains FDA Approval

article image

Saluda Medical’s Evoke System, which senses the nerves’ response to stimulation and instantaneously adjusts therapy, is the first ever closed-loop spinal cord stimulation system. Its recent FDA approval for chronic pain rests on superior efficacy seen in the most rigorous PMA study ever done in the field of neuromodulation.

In March 2022, Saluda Medical Pty Limited (Artaremon, Australia) gained FDA approval for a long-heralded and unique advancement in interventional pain: the Evoke Spinal Cord Stimulation (SCS) System , a closed loop system that, in responding to signals from an individual’s nervous system, has achieved the highest long-term rates of efficacy while addressing major challenges of other therapies, such as frequent visits for reprogramming.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: